Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 38 peer-reviewed journal articles Updated
Neurology

DPM3-CDG: A Patient Guide

At a Glance

DPM3-CDG is an ultra-rare genetic disorder that can affect muscle strength, heart health, development, and the brain. Because symptoms vary and may appear from childhood to adulthood, care focuses on coordinated specialist follow-up, routine monitoring, and early supportive services.

DPM3-CDG is an ultra-rare genetic condition that fundamentally changes how the body builds and maintains its cells. It belongs to a group of disorders known as Congenital Disorders of Glycosylation (CDG), which occur when the body’s complex system for attaching sugar molecules to proteins is interrupted [1]. These sugar attachments are not just fuel; they act as essential structural components and biological signals. In DPM3-CDG, the “factory line” for a specific sugar-building block is impaired, leaving several vital proteins—especially those that protect and stabilize muscle and brain cells—unfinished and unable to function properly [2].

The way this condition shows up is a reported spectrum that can vary significantly from one person to another. For some, the focus is primarily on the muscles and the heart, characterized by a form of muscular dystrophy that causes weakness in the hips and shoulders, alongside a risk of the heart muscle becoming thin and weakened over time [3]. For others, the condition involves a broader “muscle-and-brain” presentation, which can include developmental delays, seizures, and differences in brain structure that are visible on imaging [1]. Because these symptoms can emerge at different stages of life, from early childhood through adulthood, the condition requires a flexible and attentive approach to care.

While there is currently no single cure for DPM3-CDG, the focus of modern medicine is on proactive, supportive management that addresses each person’s unique needs. This involves a dedicated team of specialists—including neurologists to support development and cardiologists to protect heart health—working together to stay ahead of potential complications [4]. By focusing on routine monitoring and early intervention, the goal of care is to maximize mobility, support learning and communication, and ensure that the person with DPM3-CDG can maintain their health, participation, and comfort [5].

In this guide

5 chapters

01

Understanding DPM3-CDG

Learn what DPM3-CDG means, how DPM3 gene changes affect glycosylation, muscle and brain symptoms, heart risks, inheritance, and coordinated care for families.

02

Recognizing Symptoms and Warning Signs

Learn the symptoms and warning signs of DPM3-CDG, including muscle weakness, seizures, heart problems, emergency red flags, and when to seek urgent care.

03

The Path to a Clear Diagnosis

Learn how DPM3-CDG is diagnosed, why normal transferrin testing may not rule it out, and how genetic sequencing, biopsy, and family testing help confirm it.

04

Navigating Care and Safety

Learn how DPM3-CDG care supports symptoms with heart and breathing checks, safe anesthesia planning, therapy, nutrition, supplements, and regular follow-up.

05

Monitoring Growth and Health Over Time

Learn how DPM3-CDG monitoring tracks heart, breathing, seizures, development, and emotional health, including ECGs, sleep studies, and personalized follow-up.

Common questions in this guide

What is DPM3-CDG?
DPM3-CDG is an ultra-rare genetic condition in the congenital disorders of glycosylation group. It disrupts a cellular process that attaches sugar molecules to proteins, which can affect how muscle, heart, and brain cells work.
What symptoms can DPM3-CDG cause?
The condition varies widely. It may cause muscular dystrophy with weakness in the hips and shoulders, weakening of the heart muscle, developmental delays, seizures, or differences in brain structure seen on imaging.
When can DPM3-CDG symptoms begin?
Signs can appear at different stages, from early childhood through adulthood. The pattern and severity can differ substantially from one person to another, so care is tailored to the individual's needs.
Is there a cure for DPM3-CDG?
There is currently no single cure for DPM3-CDG. Care focuses on proactive supportive management, routine monitoring, and early intervention to support mobility, learning, communication, health, and comfort.
Which specialists help manage DPM3-CDG?
Care may include a neurologist and a cardiologist working with the broader support team. Neurology can help address development and related concerns, while cardiology can monitor and protect heart health; the exact team depends on the person's symptoms and needs.
What should we monitor at home with DPM3-CDG?
Ask the care team which daily changes in strength, development, seizures, communication, and overall well-being are most important to record. Sharing a simple record of changes can help the team assess whether the care plan is meeting the person's needs.
Should someone with DPM3-CDG see a rare-disease specialist or center?
Because DPM3-CDG is ultra-rare, it can be reasonable to ask whether a center or specialist with experience in congenital disorders of glycosylation should be involved. Your existing team can help decide how that consultation fits with ongoing neurology and cardiology care.

Get notified when new evidence is published on DPM3-CDG.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (5)
  1. 1

    A recurrent homozygous missense DPM3 variant leads to muscle and brain disease.

    Nagy S, Lau T, Alavi S, et al.

    Clinical genetics 2022; (102(6)):530-536 doi:10.1111/cge.14208.

    PMID: 35932216
  2. 2

    Toward understanding tissue-specific symptoms in dolichol-phosphate-mannose synthesis disorders; insight from DPM3-CDG.

    van Tol W, Michelakakis H, Georgiadou E, et al.

    Journal of inherited metabolic disease 2019; (42(5)):984-992 doi:10.1002/jimd.12095.

    PMID: 30931530
  3. 3

    Dilated cardiomyopathy and limb-girdle muscular dystrophy-dystroglycanopathy due to novel pathogenic variants in the DPM3 gene.

    Svahn J, Laforêt P, Vial C, et al.

    Neuromuscular disorders : NMD 2019; (29(7)):497-502 doi:10.1016/j.nmd.2019.05.004.

    PMID: 31266720
  4. 4

    Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

    Kang PB, Morrison L, Iannaccone ST, et al.

    Neurology 2015; (84(13)):1369-78 doi:10.1212/WNL.0000000000001416.

    PMID: 25825463
  5. 5

    A Qualitative Approach to Health Related Quality-of-Life in Congenital Muscular Dystrophy.

    Cornwall KM, Butterfield RJ, Hernandez A, et al.

    Journal of neuromuscular diseases 2018; (5(2)):251-255 doi:10.3233/JND-170252.

    PMID: 29689733

This DPM3-CDG information is for educational purposes and does not replace personalized medical advice. A neurologist, cardiologist, and other members of your care team can help tailor monitoring and treatment to your needs.